An observational study in Cutaneous Leishmaniasis, sponsored by University of Brasilia. Recruiting at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by University of Brasilia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Leishmaniasis, Cutaneous with a site in Brazil — 3 open to participants now, 3 under way, 1 of them phase 3. Leishmaniasis, Cutaneous · Brazil.
Among the 18 studies in Leishmaniasis, Cutaneous with a site in Brazil, this one is the only one that started in 2025, is the only observational one, and was the 18th registered.
104 studies on the registry are indexed under Leishmaniasis, Cutaneous; 19 are open to participants now.
Browse Leishmaniasis, Cutaneous studies →3 of the 18 studies in Leishmaniasis, Cutaneous with a site in Brazil are open now. Recruiting first, the newest first:
Drugs for Neglected Diseases · Sites in Brazil, Panama
Ages 18+
Hospital Universitário Professor Edgard Santos · Sites in Brazil
Ages 18–60
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 11 Leishmaniasis, Cutaneous studies recruiting now, 4 (36%) set no upper age limit and 3 (27%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 7 · Phase 4 2
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 105 across 21 observational studies indexed under Leishmaniasis, Cutaneous.
Median enrollment 53 across the 17 interventional studies, 90 across the 1 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 7 most frequent:
University of Brasilia is the lead sponsor of 68 studies on the registry; 14 are open to participants now.
University of Brasilia has 3 studies filed under Leishmaniasis, Cutaneous — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Leishmaniasis, Cutaneous with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational cohort study evaluates changes in high-frequency skin ultrasound findings in patients with cutaneous leishmaniasis receiving routine clinical treatment at the University Hospital of Brasilia, Brazil. The primary outcome is clinical cure assessed three months after completion of treatment. Ultrasonography will characterize dermal and hypodermal thickness, echogenicity and color Doppler vascular signals over repeated examinations. Associations of baseline clinical, histopathological, and ultrasound findings with healing will be investigated. Participants will be followed for 12 months from treatment initiation to evaluate their clinical course, including relapse.
Patients with cutaneous leishmaniasis will be enrolled consecutively in a prospective, single-center observational cohort at the Leishmaniasis Outpatient Clinic, Dermatology Service, University Hospital of Brasilia (HUB), Brazil. The treating clinicians determine antiparasitic treatment according to routine care; the research protocol does not assign treatment.
The diagnosis will follow an established composite reference standard based on a compatible clinical presentation and parasitological confirmation (for example, direct smear, culture, molecular detection, or amastigotes identified on histopathology), or corroborating non-parasitological findings when parasitological confirmation is unavailable. Histopathological specimens obtained at baseline as part of diagnostic care are available for retrospective review and correlation with clinical and ultrasonographic findings.
Serial high-frequency ultrasound using a Clarius L20 handheld linear scanner (8-20 MHz), including B-mode and color Doppler examination, will assess lesion morphology, echogenicity, dermal and hypodermal thickness, and vascularity. The ultrasound schedule is at days 0, 15, 30, 45, and 90 from initiation of treatment. Clinical follow-up will occur during treatment and for up to 12 months from treatment initiation. No investigational drugs or treatment allocation are part of this observational study.
The primary endpoint is clinical cure at three months following completion of treatment, assessed by clinical examination. Secondary analyses will characterize longitudinal ultrasound changes, the relationship of baseline clinical and histopathological findings with ultrasound features, persistence of sonographic abnormalities at initial clinical cure assessment, and exploratory association of sonographic characteristics with subsequent relapse. Ultrasound findings will not themselves define clinical cure or demonstrate parasite viability.
Individuals of any age with confirmed cutaneous leishmaniasis evaluated in the Leishmaniasis Outpatient Clinic at University Hospital of Brasilia, Brazil.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional exclusions, if any, must be verified against the approved study protocol before release.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with confirmed cutaneous leishmaniasis receiving routine clinical treatment and undergoing repeated clinical and high-frequency ultrasound assessments.
Diagnostic Test: Serial High-Frequency Cutaneous Ultrasonography
Serial B-mode and color Doppler skin ultrasonography performed with the Clarius L20 (8-20 MHz) at days 0, 15, 30, 45, and 90 after initiation of clinically indicated treatment. This imaging procedure is for observation and does not determine drug allocation.
Proportion of Participants With Clinical Cure
Percentage of evaluable participants meeting the predefined clinical cure criteria at three months after completion of treatment, based on examination for complete re-epithelialization of ulcerative lesions and resolution or flattening of active inflammatory infiltration.
Time frame: Three months after completion of routine treatment
Longitudinal Change in Dermal Thickness
Serial ultrasound measurement of dermal thickness (mm) in the followed cutaneous lesion.
Time frame: Days 0, 15, 30, 45, and 90 after treatment initiation
Longitudinal Change in Sonographic Echogenicity
Serial assessment of dermal and hypodermal lesion echogenicity on high-frequency ultrasound.
Time frame: Days 0, 15, 30, 45, and 90 after treatment initiation
Presence of Color Doppler Vascular Signal
Presence or absence of detectable color Doppler signal within the studied lesion at each scheduled visit; Doppler settings will be standardized.
Time frame: Days 0, 15, 30, 45, and 90 after treatment initiation
Association Between Baseline Ultrasound and Histopathologic Features
Exploratory assessment of associations between baseline sonographic morphological features and histopathological findings from the initially sampled lesion.
Time frame: Baseline, prior to initiation of treatment
Residual Ultrasound Abnormalities at Initial Clinical Cure Assessment
Presence of persistent sonographic dermal, hypodermal, or vascular abnormalities at the visit when clinical cure is first identified.
Time frame: At first documented clinical cure, within 12 months after treatment initiation
Occurrence of Cutaneous Leishmaniasis Relapse
Clinical recurrence of cutaneous leishmaniasis after documented initial cure; operational definition of confirmed relapse and at-risk follow-up to be finalized.
Time frame: Up to 12 months after initiation of treatment
Plan to share: Yes — deidentified study data will be published at dryad repository (https://datadryad.org/) after all publications related to the study are published
Supporting information: Study protocol
Time frame: after publication of results, one year after conclusion, abril 2029
Access criteria: Publicly evaluable, deidentified data
Data sharing details ↗ · datadryad.org
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Apr 2028, 39 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Brasilia